<DOC>
	<DOCNO>NCT01220947</DOCNO>
	<brief_summary>This randomize , open-label , active-controlled , parallel-group study evaluate sustain virological response danoprevir boost low dose ritonavir combination Pegasys ( peginterferon alfa-2a ) Copegus versus Pegasys Copegus alone treatment-naive patient chronic Hepatitis C .</brief_summary>
	<brief_title>A Study Danoprevir Boosted With Low Dose Ritonavir Combination With Pegasys Copegus Treatment-Naive Patients With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Adults patient , &gt; /=18 year age Chronic Hepatitis C , Genotype 1 4 HCV RNA &gt; /=50,000 IU/mL treatmentnaive Patients cirrhosis incomplete/transition cirrhosis Patients form liver disease , HIV infection , hepatocellular carcinoma severe cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>